The trial is designed to determine the safety and efficacy of ABP 501 compared with Adalimumab in subjects with moderate to severe rheumatoid arthritis

Mise à jour : Il y a 5 ans
Référence : EUCTR2013-000525-31

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The primary objective for this study is to assess the efficacy of ABP 501 compared with adalimumab.


Critère d'inclusion

  • Moderate to Severe Rheumatoid Arthritis